NUVISAN’s newest branch, the Innovation Campus Berlin (ICB), is deeply rooted in big pharma’s drug discovery processes across major therapeutic areas. The ICB’s capabilities and expertise cover all key aspects of successful drug identification, profiling, positioning, and de-risking, such as the following:
Our team of scientists is enthusiastic about sharing their expertise to guide your project in the most promising direction. In addition to consultancy services, our expansive research facility, housing over 500 scientists and lab professionals, offers a wide array of disease-specific in vitro assays, ex vivo assays, and in vivo models to optimize and advance your preclinical discovery strategy. Alongside 2D cell culture systems, we provide an expanding collection of disease-relevant inducible pluripotent stem cell (iPSC) lines, applicable to 2D and 3D formats, such as spheroids or organoids. We possess CRISPR/Cas9 capabilities to introduce disease-causing mutations that are particularly valuable for tackling rare monogenic or oligogenic diseases. Alternatively, patient-derived material can be used to generate tissues to study the effects of drugs on disease-related traits. iPSC-derived 3D human tissues can be integrated into high-throughput screening assays, facilitating the early identification of lead structures tailored to specific indications. Furthermore, we have a substantial repertoire of readily available disease-agnostic test systems for opportunistic use in specific applications. Examples of such systems are as follows:
Overall, our primary expertise is focused on (but not limited to) the following therapeutic areas and indications:
The platforms encompass not only established in vivo models commonly used in routine practice, such as pharmacodynamic models that delve into essential pathogenetic principles, but also intricate disease models that strive to attain a more profound comprehension of disease mechanisms. As a scientifically oriented institution, we are open to accommodating customer requirements by developing or incorporating novel technologies and research methodologies.
We strive to establish what we call “Therapeutic Solution Lines,” that is, the key capabilities needed to pursue indication-focused projects that are built up along the value chain, allowing customers and project owners to access our service lines at any conceivable entry point up to clinical proof of concept.